Search

Displaying results 3851 - 3860 of 5898 in total
  1. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper.

  2. Drug

    Irsenontrine

    go.drugbank.com/drugs/DB19044
    Investigational

    Irsenontrine is under investigation in clinical trial NCT03467152 (Study to Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia

    Synonyms: 4h-pyrazolo(4,3-c)quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4- pyridinyl)-1-((3s)-tetrahydro-3-furanyl)-, 7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-((3s)-tetrahydrofuran-3-yl)-1,5-dihydro-4h-pyrazolo(4,3-c)quinolin-4-one
  3. Drug

    Elezanumab

    go.drugbank.com/drugs/DB15240
    Investigational

    Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).

  4. Drug

    Afabicin

    go.drugbank.com/drugs/DB15268
    Investigational

    Afabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

  5. Drug

    D-1,4-dithiothreitol

    go.drugbank.com/drugs/DB02184
    Experimental

    A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]

  6. Drug

    Semorinemab

    go.drugbank.com/drugs/DB15234
    Investigational

    Semorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease).

  7. Drug

    Fenthion

    go.drugbank.com/drugs/DB11412
    ExperimentalVet approved

    Fenthion is listed as a restricted use compound by the United States Environmental Protection Agency due to its potential to cause cholinesterase inhibition in humans and animals. … Its mode of action is explained by cholinesterase enzyme inhibition, which is similar to other organophosphates.

    Synonyms: O,O-Dimethyl O-4-methylthio-m-tolyl phosphorothioate, O,O-Dimethyl O-[3-methyl-4-(methylsulfanyl)phenyl] thiophosphate
  8. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Thus, the media in which they are cultured is believed to also have therapeutic potential. … When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are thought to reduce inflammation and associated damage.

  9. Drug

    7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

    go.drugbank.com/drugs/DB08550
    Experimental

    Potent reversible inhibitor of phenylethanolamine N-methyltransferase.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.